BPC-157 and TB-500 are peptide names. This page explains what the approval and pharmacy rules mean for these substances.
For a recovery claim, ask what was studied in people with the same injury as yours. Keep that question separate from whether a product has approval.
BPC-157 had no U.S. approval
FDA, the U.S. Food and Drug Administration, handles approval of medicines.
The FDA search dated September 26, 2026 found no BPC-157 file for a request to approve a medicine.
The records behind this guide give no result from a study of injury healing in people taking this peptide. This guide cannot say whether it speeds healing or by how much. That does not mean no study has ever been done.
Can a pharmacy make either peptide for you?
Compounding means that a pharmacist or doctor makes a custom medicine.
A pharmacy may prepare a custom medicine for someone named on a prescription. These peptides do not meet the raw-ingredient rules for that kind of pharmacy care.
One way a raw ingredient can qualify is to appear on FDA’s list of extra allowed ingredients.
Neither peptide is on that list. In July 2026, FDA also said neither had the required written drug-quality standard or was part of an approved drug. Those are the other ways an ingredient can qualify.
Before the July 2026 meeting, FDA staff advised against adding TB-500 or BPC-157 to that list.
Taking back a request is not permission
The groups that asked for BPC-157 and TB-500 to be allowed later took back their requests. FDA kept both cancelled requests on a page with the content date April 22, 2026. FDA still displayed its safety concerns beside both names.
FDA’s concerns include the body reacting to an injected peptide and uncertainty about what is in the vial. Human safety information is missing or limited.
A cancelled request leaves the pharmacy’s ingredient rules unchanged.
A committee vote would not change the rules
By September 26, 2026, no official FDA account of the July committee votes had been found. The vote result is unknown here; that does not mean no vote took place.
The committee only advises FDA. FDA must invite public comments and formally change the rules before it can add an ingredient to the allowed list.